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Is D2B the Only Metric to Determine
Outcome With STEMI?
We appreciate Dr. Conti’s remarks highlighting the recent conundrum
of lower door-to-balloon times not equating to reduced mortality or
30-day readmission rates in our paper (1) as well as that reported
in another recent publication (2). As we disclosed in the discussion, our
4-year study began in 2007 at a time when many demographics
nationwide, including symptom onset, ﬁrst medical contact, and total
ischemia time, also knownas symptom-to-balloon (S2B) time,werenot
identiﬁed tracking elements. Fortunately,many regional systemsof care
have now incorporated these into their data acquisition through the
ACTION (Acute Coronary Treatment and Intervention Outcome
Network) Registry–Get With the Guidelines, and indeed we began
adopting these in 2009 as we recently reported at the 2013 Trans-
catheter Cardiovascular Therapeutics Conference (3,4). Even so, these
are not the entire universe of important metrics regarding acute
ST-segment elevation myocardial infarction treatment. Oh, how we
wish we could quantitate preservation of ejection fraction, lower
morbidity associated with less heart failure, and quality of life measures,
to name a few. It is not good enough to presume that these are improved
by better door-to-balloon times, but it does seem intuitive. As has been
said by the North Carolina RACE-ER (Reperfusion of Acute
myocardial infarction inCarolina Emergency departments-Emergency
Response) investigators Dr. Jollis, Dr. Granger, and Ms. Roettig, a
door-to-balloon time <90 min has largely been solved by most well-
functioning hospitals in this country and abroad (5). Only through
achieving the overarching goal of reducing total ischemia time or
S2B time through coordinated regional systems of care may we be able
to further reduce an already low ST-segment elevation myocardial
infarction mortality rate and improve outcomes. It is hoped that our
paper and the 5 or so tools that we described may be useful in helping
systems reach these goals. We all need to continue work on S2B time
and extended outcomes measures.
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Renal Denervation of
Accessory Renal Arteries
In the October issue of JACC: Cardiovascular Interventions, Id et al.
(1) compared the results of renal denervation using the Symplicity
catheter system (Medtronic, Mountain View, California) in patients
with and without accessory renal arteries. This issue is not insig-
niﬁcant considering that 27% of the resistant hypertension popu-
lation may have accessory renal arteries. These patients have, for the
most part, been excluded from clinical trials of renal denervation
devices. The drop in ofﬁce-based systolic blood pressure at 6
months was signiﬁcantly less in the patients with accessory renal
arteries than in those with only main renal artery trunks (–6.2 mmHg
vs. –16.6 mm Hg). The patients with accessory renal arteries were
further subdivided into 2 groups; the subgroup with complete
accessory renal artery denervation experienced a slightly greater drop
in systolic blood pressure than did patients with incomplete treat-
ment of their accessory arteries (–8.8 mm Hg vs. –4.1 mm Hg).
Renal denervation targets the sympathetic nerves located in the
adventitia of the renal artery wall (2). The nerves travel from the
spinal cord along the artery and then to the kidney where extensive
branching occurs. Early anatomic studies using electron microscopic
autoradiography demonstrated that the majority of renal nerves
terminate at vascular structures within the kidney (3). Based on
these anatomic ﬁndings, the nerve trafﬁc to and from the kidney
corresponds at least roughly to the blood supply, traveling with both
accessory and main renal arteries. So patients with accessory renal
arteries may be predisposed to a lack of blood pressure response if
treated with a denervation technique targeting nerves only in the
main renal arterydjust as was reported in the article by Id et al. (1).
Yet, why was the blood pressure-lowering response in the sub-
group with “complete” renal denervation of accessory renal arteries
less than that in the group with only main renal artery trunks? This
difference may in part be explained by limitations of the monopolar
renal denervation system used for ablation of accessory renal
arteries. Cooling of monopolar catheters from blood ﬂow is critical
to avoid tissue damage from catheter overheating. In low ﬂow
conditions such as with accessory renal arteries, cooling may be
inadequate. The system generator will then terminate energy
delivery to prevent overheating, but it also halts the ablation,
potentially compromising denervation efﬁcacy. Other renal dener-
vation systems that do not require cooling may be more effective for
accessary renal arteries (4). It will be critical to understand the
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341differences in renal denervation technologies and their applicability
to the subset of patients with accessory renal artery anatomy.
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Reply
Renal Denervation of Accessory
Renal Arteries
We appreciate the interest and comments of Dr. Mendelsohn
regarding our recently published paper (1). The paper described the
blood pressure–lowering effect of catheter-based renal denervation
in patients with bilateral single renal arteries compared with those
with accessory renal arteries.
As outlined in our paper, systolic blood pressure reduction was
less pronounced in patients with accessory renal arteries (regardless
of complete or incomplete denervation). Furthermore, blood
pressure reduction, even in patients with complete denervation of
accessory renal arteries, was numerically less pronounced than in
patients with bilateral single renal arteries; however, this difference
did not reach statistical signiﬁcance. We postulated that the latterobservation might have been related to a true absence of a differ-
ence in blood pressure reductions or to a true difference that did not
reach statistical signiﬁcance due to insufﬁcient power, a result of the
limited number of patients in the respective subgroups. Studies
with larger patient numbers and adequate power to clarify the
importance of complete denervation including accessory renal
arteries are needed. We agree with Dr. Mendelsohn that, provided
these studies conﬁrm a less pronounced blood pressure reduction in
patients with accessory renal arteries, this may be the result of
incomplete denervation due to technical limitations related to
overheating as a consequence of insufﬁcient cooling by altered ﬂow
dynamics in accessory renal arteries. It is also possible that limited
maneuverability of the catheter used in our study in smaller caliber
arteries interferes with circumferential energy application, perhaps
preventing complete denervation. In this context, potential solu-
tions are being actively pursued by a number of companies. These
may include, but are not limited to, irrigated radiofrequency
catheter systems, lower proﬁle catheters with superior maneuver-
ability that do not interfere with ﬂow dynamics in smaller vessels,
the use of a cooling balloon during energy delivery, chemical
neurolysis, or noninvasive denervation. Some of these technologies
have reached the clinical stage and approval for use in some
countries. It will now be very important to examine the efﬁcacy
(and safety) of these technologies in smaller accessory renal arteries.
Hence, studies examining devices that allow application in smaller
(<4 mm) caliber arteries should not exclude patients with accessory
renal arteries.
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